Why has immunotherapy failed in glioblastoma so far?
The main reason is that glioblastoma creates a highly immunosuppressive environment that blocks the immune system from attacking the tumor. Unlike many other cancers, GBM has a 'cold' immune microenvironment with few active T cells, and it actively suppresses any immune response that does develop [5][6]. The blood-brain barrier (BBB) also physically prevents many immunotherapeutic drugs and immune cells from reaching the tumor [2][3]. These barriers are so effective that even powerful immune checkpoint inhibitors (ICIs) like nivolumab and pembrolizumab have failed to improve survival in large phase III trials, including CheckMate 143 and CheckMate 498 [7][10].
The tumor itself is also highly heterogeneous, meaning different parts of the same tumor can have different genetic mutations and antigens. This makes it difficult for therapies like vaccines or CAR-T cells that target a single antigen to eliminate all cancer cells [11][12]. As one review notes, 'the disease has proven to be highly resistant to treatment due to a combination of tumor heterogeneity, adaptive expansion of resistant cellular subclones, evasion of immune surveillance, and manipulation of various signaling pathways' [12].
Are there any promising immunotherapy approaches for glioblastoma?
Yes, several strategies are being actively investigated, and some have shown encouraging results in early-stage trials, though none are yet standard of care. One approach is combination therapy, which aims to overcome the tumor's defenses by attacking from multiple angles. For example, combining immune checkpoint inhibitors with radiation, chemotherapy, or other immunotherapies has shown more immune activation than single agents alone, even if survival benefits remain unproven [6][7].
Dendritic cell (DC) vaccines, which train the immune system to recognize tumor cells, have shown some of the most promising survival data. In a small study of 5 pediatric patients with recurrent high-grade gliomas, a combination of autologous DC vaccine and donor immune cells resulted in a 2-year overall survival rate of 58%, with one patient with glioblastoma surviving over 13 years without further treatment [1]. The DCVax-L vaccine platform has also shown 'promising survival outcomes in clinical trials' [13].
Another active area is improving drug delivery across the blood-brain barrier. Researchers have developed lipid nanoparticle systems that can carry siRNA or other therapies into the brain. One such system, tested in mice, successfully delivered siRNA to silence the immune-suppressing proteins CD47 and PD-L1 within the tumor, leading to T-cell activation and tumor shrinkage [3]. A similar nanoparticle platform also showed it could penetrate the BBB and enhance dendritic cell maturation and T-cell activation in mouse models [2].
What does the future look like for glioblastoma immunotherapy?
The future likely lies in personalized combination therapies that are tailored to each patient's tumor. Because GBM is so heterogeneous and immunosuppressive, a single drug is unlikely to work for everyone. Researchers are now focusing on identifying biomarkers to predict which patients might respond to which therapy, and on developing multi-antigen vaccines that can target multiple parts of the tumor at once [9][11][12].
Cellular therapies like CAR-T cells are also being redesigned to overcome antigen variability and the blood-brain barrier. Newer CAR-T designs can target multiple antigens and are being combined with other agents to improve their ability to enter the brain and persist in the tumor microenvironment [13]. Oncolytic viruses, which infect and kill cancer cells while also stimulating an immune response, are another avenue being explored in combination with other immunotherapies [4][8].
Ultimately, the consensus across the research is clear: 'Immunotherapeutics that are efficacious in other cancer types have unfortunately not enjoyed the same success in glioblastoma, illustrating the challenging and complex nature of this disease and demonstrating the need for development of multimodal treatment regimens' [12].
About These Sources
This answer is built on 13 peer-reviewed studies — published from 2021 to 2025, 7 from 2024 or later, 6 in Q1 journals, collectively cited 551 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 61 papers retrieved from a database of over 500 million.
Sources used in this answer
Immunotherapy for children with malignant brain tumors
In a small study of 5 pediatric patients with recurrent high-grade gliomas, a combination of autologous dendritic cell vaccine and donor immune cells resulted in a 2-year overall survival rate of 58%, with one glioblastoma patient surviving over 13 years.
A blood–brain barrier- and blood–brain tumor barrier-penetrating siRNA delivery system targeting gliomas for brain tumor immunotherapy
A lipid nanoparticle platform with a dual-functional peptide was shown in mice to penetrate the blood-brain barrier, enhance dendritic cell maturation, and activate cytotoxic T cells against glioma.
An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy
A new cationic lipid nanoparticle (BAMPA-O16B) effectively delivered siRNA across the BBB in mice, silencing CD47 and PD-L1 in the tumor and activating T-cell-dependent antitumor immunity in orthotopic GBM.
Advances in immunotherapy for glioblastoma multiforme
This review identifies immune checkpoint inhibitors, oncolytic viruses, nonreplicating viral vectors, and CAR-T cell therapies as the most promising immunotherapy candidates for glioblastoma in clinical trials.
Immunotherapy for brain metastases and primary brain tumors
Current immunotherapies have failed to deliver meaningful clinical benefit in primary brain tumors like glioblastoma, largely due to the blood-brain barrier and a highly immunosuppressive microenvironment, unlike brain metastases which often respond.
Combinatory Immunotherapy for Glioblastoma Treatment
Conventional single-agent immunotherapies for GBM often fail due to the 'cold' immune microenvironment, but combination approaches (e.g., chemo-immunotherapy, radio-immunotherapy) show promise in modulating the tumor immune microenvironment.
Combination immunotherapy strategies for glioblastoma
The CheckMate 143 and 498 trials showed that the immune checkpoint inhibitor nivolumab failed to improve overall survival in recurrent and newly diagnosed GBM, though neoadjuvant ICB did show immune modulation (e.g., increased T-cell receptor diversity).
Current Immunotherapies for Glioblastoma Multiforme
This review notes that peptide vaccines, dendritic cell vaccines, CAR-T cells, checkpoint inhibitors, and oncolytic virotherapy have achieved some promising results in preclinical and clinical trials for GBM.
Investigating the Impact of Immunotherapy on Brain Tumors
Immunotherapy shows promise for glioblastoma, but challenges remain including the blood-brain barrier and immunosuppressive tumor microenvironment; combination therapies and personalized approaches are being explored.
Immunotherapy in Glioblastoma.
Immunotherapies for glioblastoma have shown limited success, with negative trials for vaccines and immune checkpoint inhibitors failing to demonstrate survival improvement, though they have provided insights into hurdles to overcome.
Opportunities to Modulate Tumor Ecosystem Toward Successful Glioblastoma Immunotherapy.
Current immunotherapies for GBM remain largely ineffective due to the complex tumor microenvironment; strategies include targeting multiple antigens and identifying new druggable targets to abrogate immunosuppression.
Current Advances in Immunotherapy for Glioblastoma
Immunotherapies effective in other cancers have not enjoyed the same success in glioblastoma due to tumor heterogeneity, immune evasion, and T-cell dysfunction; multi-antigen vaccines and combinatorial approaches are being developed.
Immunotherapy in Glioblastoma: An Overview of Current Status
Immune checkpoint inhibitors, CAR-T cell therapies, and dendritic cell-based vaccines like DCVax-L have shown promising survival outcomes in clinical trials for glioblastoma, with combination strategies being developed to enhance immune response.